Scholarlink

Aims/hypothesis <p>The aim of this study was to determine the effect of a novel somatostatin receptor 2 (SSTR2) antagonist, ZT-01, on impaired glucagon counterregulation in hypoglycaemia and its safety in adults with type 1 diabetes.</p> Methods <p>In a randomised crossover phase 1b single-site study, blinded to both participants and researchers, participants, aged 18–65 years with BMI 18.5–27 kg/m<sup>2</sup> with type 1 diabetes (HbA<sub>1c</sub> 42.1–74.9 mmol/mol and C-peptide &lt;200 pmol/l) underwent three separate hyperinsulinaemic euglycaemic–hypoglycaemic clamps. Participants were randomised, by a third party, in equal proportion to treatment order with placebo, 3 mg ZT-01 or 20 mg ZT-01 administered subcutaneously during euglycaemia (plasma glucose target 5.0 mmol/l), and exposed to level 1 (target 3.5 mmol/l) and level 2 (target 2.6 mmol/l) hypoglycaemia induced with variable-rate insulin infusion without addition of dextrose. Glucagon response was the primary endpoint; plasma glucose, other counterregulatory hormones, symptom scores and safety were also determined.</p> Results <p>Twenty-four randomised participants (9 female and 15 male) received at least one administration of placebo or ZT-01 and were included for safety analysis. Twenty-two participants completed at least one glucose clamp and were included for pharmacodynamics analysis. Transient increases in plasma glucagon were observed with ZT-01 administration (by 25.7&#xa0;±&#xa0;2.4 ng/l with 3 mg ZT-01 and by 28.4&#xa0;±&#xa0;2.4 ng/l with 20 mg ZT-01), with levels declining to near the pre-dose values before the start of the level 1 hypoglycaemic period. Mean glucagon levels rose again over baseline in both ZT-01 treatment arms during level 1 (by 15.6&#xa0;±&#xa0;2.3 pg/l with 3 mg ZT-01 and by 14.9&#xa0;±&#xa0;2.4 pg/l with 20 mg ZT-01) and level 2 (by 22.8&#xa0;±&#xa0;2.7 pg/l with 3.0 mg ZT-01 and by 29.6&#xa0;±&#xa0;2.8 pg/l with 20 mg ZT-01) hypoglycaemia. With placebo, glucagon levels were unchanged following dosing and during level 1 hypoglycaemia but rose modestly during level 2 hypoglycaemia (by 8.9&#xa0;±&#xa0;2.5 ng/l). Both frequency and amplitude of the increases in glucagon were higher with ZT-01 vs placebo during level 1 and level 2 hypoglycaemia. There were no drug treatment-related adverse events.</p> Conclusions/interpretation <p>Administration of the SSTR2 antagonist ZT-01 increased glucagon responsiveness during insulin-induced hypoglycaemia in individuals with type 1 diabetes.</p> Trial registration <p>ClinicalTrials.gov NCT05007977</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic–hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Alexander Abitbol,
  • Michael C. Riddell,
  • Susan Peers,
  • Eric Simonson,
  • Mark Evans,
  • Filip K. Knop,
  • Richard T. Liggins

摘要

Aims/hypothesis

The aim of this study was to determine the effect of a novel somatostatin receptor 2 (SSTR2) antagonist, ZT-01, on impaired glucagon counterregulation in hypoglycaemia and its safety in adults with type 1 diabetes.

Methods

In a randomised crossover phase 1b single-site study, blinded to both participants and researchers, participants, aged 18–65 years with BMI 18.5–27 kg/m2 with type 1 diabetes (HbA1c 42.1–74.9 mmol/mol and C-peptide <200 pmol/l) underwent three separate hyperinsulinaemic euglycaemic–hypoglycaemic clamps. Participants were randomised, by a third party, in equal proportion to treatment order with placebo, 3 mg ZT-01 or 20 mg ZT-01 administered subcutaneously during euglycaemia (plasma glucose target 5.0 mmol/l), and exposed to level 1 (target 3.5 mmol/l) and level 2 (target 2.6 mmol/l) hypoglycaemia induced with variable-rate insulin infusion without addition of dextrose. Glucagon response was the primary endpoint; plasma glucose, other counterregulatory hormones, symptom scores and safety were also determined.

Results

Twenty-four randomised participants (9 female and 15 male) received at least one administration of placebo or ZT-01 and were included for safety analysis. Twenty-two participants completed at least one glucose clamp and were included for pharmacodynamics analysis. Transient increases in plasma glucagon were observed with ZT-01 administration (by 25.7 ± 2.4 ng/l with 3 mg ZT-01 and by 28.4 ± 2.4 ng/l with 20 mg ZT-01), with levels declining to near the pre-dose values before the start of the level 1 hypoglycaemic period. Mean glucagon levels rose again over baseline in both ZT-01 treatment arms during level 1 (by 15.6 ± 2.3 pg/l with 3 mg ZT-01 and by 14.9 ± 2.4 pg/l with 20 mg ZT-01) and level 2 (by 22.8 ± 2.7 pg/l with 3.0 mg ZT-01 and by 29.6 ± 2.8 pg/l with 20 mg ZT-01) hypoglycaemia. With placebo, glucagon levels were unchanged following dosing and during level 1 hypoglycaemia but rose modestly during level 2 hypoglycaemia (by 8.9 ± 2.5 ng/l). Both frequency and amplitude of the increases in glucagon were higher with ZT-01 vs placebo during level 1 and level 2 hypoglycaemia. There were no drug treatment-related adverse events.

Conclusions/interpretation

Administration of the SSTR2 antagonist ZT-01 increased glucagon responsiveness during insulin-induced hypoglycaemia in individuals with type 1 diabetes.

Trial registration

ClinicalTrials.gov NCT05007977

Graphical Abstract